GSE135350 XPO1 inhibition Dexamethasone 2 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE135350_XPO1 inhibition_Dexamethasone_2_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE135350_XPO1 inhibition_Dexamethasone_2_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE135350_XPO1 inhibition_Dexamethasone_2_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE135350_XPO1 inhibition_Dexamethasone_2_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

MSL complex subunit 3B

Gene

PAX8 antisense RNA 1

Gene

small nucleolar RNA host gene 17

Gene

long intergenic non-protein coding RNA 632

Gene

MIR924 host gene

Gene

ribosomal protein SA pseudogene 52

Gene

long intergenic non-protein coding RNA 3104

Gene

HMGA2 antisense RNA 1

Gene

ribosomal protein L23a pseudogene 21

Gene

LCT antisense RNA 1

  • Gene

    MSL complex subunit 3B


  • Gene

    PAX8 antisense RNA 1


  • Gene

    small nucleolar RNA host gene 17


  • Gene

    long intergenic non-protein coding RNA 632



  • Gene

    ribosomal protein SA pseudogene 52


  • Gene

    long intergenic non-protein coding RNA 3104


  • Gene

    HMGA2 antisense RNA 1


  • Gene

    ribosomal protein L23a pseudogene 21


  • Gene

    LCT antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.